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PCardiac Imaging: Viewpoint
he Potential of Myocardial
erfusion Scintigraphy for Risk Stratification
f Asymptomatic Patients With Type 2 Diabetes
eroen J. Bax, MD,* Robert O. Bonow, MD,† Diethelm Tschöpe, MD,‡ Silvio E. Inzucchi, MD,§
ugene Barrett, MD, on behalf of the Global Dialogue Group for the Evaluation of Cardiovascular
isk in Patients With Diabetes
eiden, the Netherlands; Bad Oeynhausen, Germany; Chicago, Illinois; New Haven, Connecticut;
nd Charlottesville, Virginia
Patients with diabetes, in particular patients with type 2 diabetes, are at a 2- to 4-fold higher
risk of cardiovascular mortality compared with their nondiabetic peers. Patients with diabetes
are also more likely to have silent ischemia and less likely to survive a myocardial infarction
than nondiabetic patients. Recent studies with electron beam computed tomography (EBCT)
have shown that subclinical atherosclerosis is common in patients with diabetes, and studies
with myocardial perfusion scintigraphy (with single-photon emission computed tomography)
or stress echocardiography have demonstrated that between 25% and 50% of asymptomatic
diabetic patients have ischemia during exercise or pharmacological stress and that a substantial
proportion of these patients go on to develop major cardiovascular events within several years.
Clearly, asymptomatic diabetic patients include a subset of individuals at high risk of
cardiovascular disease who would benefit from improved risk stratification beyond that
possible with risk factor scoring systems alone. Single-photon emission computed tomogra-
phy, stress echocardiography, and possibly EBCT or multi-slice computed tomography, are
emerging as valuable diagnostic tools for identifying asymptomatic diabetic patients who
might require early and aggressive intervention to manage their cardiovascular risk. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.077Coll Cardiol 2006;48:754–60) © 2006 by the American College of Cardiology Foundation
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Management guidelines in Europe (1) and the U.S. (2)
onsider type 2 diabetes to be a cardiovascular disease
quivalent. Patients with type 2 diabetes have a 2- to 4-fold
igher risk of a cardiovascular event than nondiabetic
atients (3), and Haffner et al. (3) have shown that the risk
f myocardial infarction (MI) in a diabetic patient is
omparable to the risk of recurrent infarction in a nondia-
etic patient with a previous MI (Fig. 1). However, other
tudies suggested a lower prevalence of MI in diabetic
atients, and the exact prevalence of cardiovascular events in
symptomatic diabetic patients remains unclear (4–6).
Still, cardiovascular disease is the principal cause of death
n patients with type 2 diabetes (1,2). The relationship
etween cardiovascular risk and cardiovascular outcomes
iffers importantly between type 2 diabetic and nondiabetic
atients. Silent myocardial ischemia is more common
mong diabetic patients compared with nondiabetic patients
From the *Leiden University Medical Center, Leiden, the Netherlands; ‡Univer-
ity Hospital of the Ruhr-University Bochum, Bad Oeynhausen, Germany; †North-
estern University Feinberg School of Medicine, Chicago, Illinois; §Yale University
chool of Medicine, New Haven, Connecticut; and the University of Virginia,
harlottesville, Virginia. The Global Dialogue Group for the Evaluation of Cardio-
ascular Risk in Patients With Diabetes was supported by an unrestricted educational
rant by Bristol-Myers Squibb Inc.i
Manuscript received July 4, 2005; revised manuscript received April 6, 2006;
ccepted April 18, 2006.7), and diabetic patients are less likely to survive a first MI
han their nondiabetic peers (8).
An increasing prevalence of obesity and sedentary life-
tyles is expected to drive the number of individuals with
iabetes worldwide to more than 330 million by the year
025 (9). The burden of cardiovascular disease and prema-
ure mortality associated with diabetes will also increase
teeply in the coming years, reflecting the increased num-
ers of younger adults and adolescents with type 2 diabetes.
ardiologists will be at the forefront of dealing with this
herapeutic challenge. There is a clear need to identify patients
ith type 2 diabetes who are at risk of cardiovascular events
efore the onset of symptoms. Accordingly, early identification
f atherosclerosis and ischemia is needed. In addition, evidence
s accumulating that myocardial perfusion scintigraphy (MPS)
s a particularly promising approach for risk stratification
ithin the population of diabetic patients who do not have
ymptoms of coronary artery disease (CAD). A group of
hysicians from Europe and the U.S. (the Global Dialogue
roup for the Evaluation of Cardiovascular Risk in Patients
ith Diabetes) recently met to consider the problem of
etecting CAD and silent ischemia in asymptomatic diabetic
atients. This viewpoint summarizes the evidence supporting
PS as a diagnostic tool for identification of CAD and silentschemia in asymptomatic diabetic patients. Moreover, a rec-
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August 15, 2006:754–60 Diagnosing Silent Ischemia in Type 2 Diabetesmmendation for the place of MPS in management algo-
ithms for this vulnerable patient population is discussed.
ETECTION OF CAD WITH
YOCARDIAL PERFUSION IMAGING
N PATIENTS WITH TYPE 2 DIABETES
revalence. The recently-published initial data from the
IAD (Detection of Silent Myocardial Ischemia in Asymp-
omatic Diabetics) study (10) have highlighted the scale of
he problem of CAD and silent ischemia in a population of
,123 asymptomatic diabetic patients. A middle-aged or
lderly patient population (mean age 61 years) and high
roportions of patients with dyslipidemia (58%), hypertension
65%), a history of smoking (58%), or at least 2 cardiovascular
isk factors (60%) indicated a population at substantial risk of
AD. Patients were randomized to undergo adenosine elec-
rocardiography (ECG)-gated technetium-99m sestamibi
ingle-photon emission computed tomography (SPECT) plus
ollow-up (n 561, with 522 patients having evaluable scans)
r to clinical follow-up only (n  562). Studies were
bnormal in 22% of the MPS group, and 16% showed
vidence of myocardial perfusion abnormalities, whereas the
emainder revealed stress-induced ECG abnormalities or
eft ventricular function abnormalities indicating ischemia
Fig. 2). Perfusion abnormalities were reversible in 88% of
hese patients (indicating ischemia), although 4% demon-
trated irreversible abnormalities (indicating scar tissue),
nd 8% demonstrated both reversible and irreversible per-
igure 1. Diabetes confers the same risk of myocardial infarction (MI) in
patient without history of MI as a prior MI in a nondiabetic patient. Data
re from an observational study of 1,373 nondiabetic subjects and 1,059
Abbreviations and Acronyms
CAD  coronary artery disease
DIAD  Detection of Silent Myocardial Ischemia in
Asymptomatic Diabetics study
EBCT  electron beam computed tomography
ECG  electrocardiography/electrocardiogram
MI  myocardial infarction
MPS  myocardial perfusion scintigraphy
MSCT  multi-slice computed tomography
SPECT  single-photon emission computed tomographye
iabetic subjects in Finland after 8 years of follow-up. On the basis of data
resented by Haffner et al. (3).usion defects (Fig. 2). The perfusion defect involved more
han 5% of the left ventricle in 40% of patients with an
bnormal SPECT study (Fig. 2). Importantly, assessment
f most established and emerging clinical and biochemical
isk factors for cardiovascular disease did not predict which
he DIAD study patients would exhibit abnormal perfusion.
owever, cardiac neuropathy was an independent predictor
f abnormal MPS. This issue might be of clinical value to
dentify high-risk diabetic patients and might have impli-
ations for aggressive medical therapy (e.g., additional
eta-blocking therapy).
The results of the DIAD study (in terms of prevalence of
bnormal MPS) are consistent with other studies in popu-
ations of diabetic patients who were asymptomatic for
AD (Table 1), in which the prevalence of abnormal
erfusion scans ranged from 21% to 59% (10–24). More-
ver, 1 of these studies reported that the prevalence of
erfusion abnormalities was comparable between asymp-
omatic diabetic patients and patients presenting with
ymptoms suggesting CAD (angina pectoris and/or dys-
nea) (14). On the basis of these observations, it is clear that
ilent ischemia is common among type 2 diabetic patients
ho have yet to develop symptoms of CAD. It should,
owever, also be emphasized that the prevalence of ischemia
aried significantly between these different reports and that
ot much is known about the extent to which ischemia is
linically (and prognostically) meaningful. These differences
an (at least partially) be attributed to the differences in
tudy populations. The majority of the studies have
ncluded small numbers of patients, and even the largest
tudies (with more than 500 patients undergoing MPS)
hat are currently available (10,13,14,16,24) have impor-
ant differences in characteristics of study populations.
he DIAD trial is the only prospective trial, whereas the
ther studies are retrospective analyses. Patients with
bnormal ECGs were excluded in the DIAD trial (10)
ut were included in the other studies. Also, 1 study
ncluded a substantial percentage of patients who needed
re-operative evaluation (16).
ssociation with adverse clinical outcomes. Several of
he aforementioned studies followed up asymptomatic dia-
etic patients to establish the relationships between abnor-
al MPS scans and adverse cardiovascular outcomes. The
tudy that enrolled 3 subsets of patients (without symptoms,
ith angina, and with dyspnea) reported that the annual
ritical event rates (MI or cardiac death) were about 3-fold
igher in patients with abnormal SPECT results (5.4% in
atients with perfusion abnormalities on SPECT vs. 1.9%
n patients with normal SPECT) in the overall study
opulation (14). Importantly, the risk of these events did
ot differ significantly between asymptomatic patients and
atients with angina.
The available data in asymptomatic diabetic patients
onfirm the results in the general population in that patients
ith a high-risk MPS have an elevated risk for adverse
vents, whereas patients with a normal MPS are at low risk.
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Diagnosing Silent Ischemia in Type 2 Diabetes August 15, 2006:754–60till, in the general population, the annual hard event rate
death or MI) is 1% (25), whereas the event rate in
iabetic patients with a normal MPS might be higher, as
mphasized recently (26).
Still, various studies reported significant associations
etween the incidence of major cardiovascular events, de-
ned as cardiac death or nonfatal MI (odds ratio 5.7, p 
.03) or nonfatal MI (odds ratio 2.9, p  0.04) (15), a
igher likelihood of 3-vessel CAD in diabetic versus non-
iabetic subjects (13), or higher rates of revascularization in
atients with abnormal SPECT scans (12,13). Overall,
hese studies showed that SPECT added important prog-
ostic information to that provided by standard risk factor
ssessment alone and also provided valuable guidance for
electing therapy for these patients.
LACE OF MPS IN RISK STRATIFICATION FOR TYPE 2
IABETES PATIENTS WITHOUT SYMPTOMS OF CAD
omparison with other noninvasive modalities. Single-
hoton emission computed tomography has important ad-
antages over other noninvasive modalities for detecting
yocardial ischemia. Exercise testing is well-established
nd well-validated in patients with known CAD, but its
ensitivity is low in patients with early atherosclerotic
hanges, and this method is less well studied in the
symptomatic diabetic population (27). In addition, many
atients with diabetes, especially those with obesity, periph-
ral vascular disease, or neuropathy, are unable to perform
dequate exercise to provide useful end points. The sensi-
ivity and specificity of stress (exercise or pharmacological)
chocardiography seem similar to SPECT (28), and recent
ata obtained in patients undergoing contrast echocardiog-
aphy are promising (29), although reproducibility and
igure 2. Prevalence and characteristics of abnormal single-photon emissio
rtery disease: data from the DIAD (Detection of Silent Myocardial Ischem
t al. (10).uantification of echocardiographic approaches might be Mess developed than with SPECT. The value of other
oninvasive imaging modalities (such as magnetic resonance
maging, electron beam computed tomography [EBCT],
nd multi-slice computed tomography [MSCT]) has not
een explored extensively in asymptomatic diabetic patients.
roposed algorithm for risk stratification in asymptom-
tic diabetic patients. Current guidelines and reports from
uropean and U.S. expert societies in cardiovascular med-
cine recognize the potential utility of MPS in risk stratifi-
ation of diabetic patients but do not widely recommend its
se in patients without symptoms of CAD (1,2,30–32).
ather, these documents tend to concentrate on patients
resenting with evidence of CAD. Given the rapid advances
n the understanding of the extent and prognostic impor-
ance of the problem of silent ischemia in the diabetic
opulation, extension of these guidelines to address these
evelopments might be considered.
On the basis of the emerging evidence in published
eports, a potential algorithm for risk stratification of
symptomatic diabetic patients could be proposed (Fig. 3),
lthough much more data are needed before a definitive
lgorithm can be developed and implemented in the
linical setting. Cardiovascular risk scoring (e.g., with the
ell-known risk engines derived from the Framingham
tudy or the UK Prospective Diabetes Study) is used to
dentify asymptomatic diabetic patients at low risk, who
ould be followed up conservatively with risk factor
odification. Of note, patients with an abnormal ECG
ndicating previous infarction or ischemia should be
eferred for stress testing according to the Guidelines of
he American Diabetes Association (32). Indeed, it was
ecently demonstrated that the presence of Q waves on
he ECG was highly predictive of a severely abnormal
puted tomography scans in diabetic patients without evidence of coronary
symptomatic Diabetics) study. On the basis of data presented by Wackersn comPS (16).
c
t
i
b
c
a
c
p
p
r
a
d
e
r
i
p
a
i
I
M
T
*
i
e
757JACC Vol. 48, No. 4, 2006 Bax et al.
August 15, 2006:754–60 Diagnosing Silent Ischemia in Type 2 DiabetesPatients with moderate to high risk (on the basis of
ardiovascular risk scoring) might be referred for MPS. On
he basis of the extent and severity of perfusion abnormal-
ties, additional evaluation, treatment, and follow-up could
e planned. Patients with mild perfusion abnormalities
ould be treated conservatively with risk factor modification,
ggressive medical therapy, and follow-up MPS. It is
urrently unclear how frequent follow-up MPS should be
erformed, but the available data suggest that the warranty
eriod of a normal MPS in patients with diabetes is in the
ange of 1 to 3 years; a follow-up MPS could be proposed
able 1. Evidence for Silent Ischemia in Diabetic Patients Witho
Reference n* Patient Characteristics
10† 1,123 Type 2 DM without clinically
apparent CAD
Gated 9
adeno
feasib
11 56 Type 1 or 2 DM with 3 CV
risk factors
201Tl SP
12 180 DM patients with multiple CV
risk factors
99mTc s
dipyr
13 1,738 DM patients without clinically
apparent CAD
201Tl or
exerc
dipyr
14 1,737 826 were asymptomatic, 151 had
shortness of breath, 760 had
angina pectoris
Rest 201
SPEC
(n 
15 158 DM patients mostly asymptomatic
for CAD (78%) with 2 CV
risk factors
201T1 S
dipyr
16 1,427 DM patients without clinically
apparent CAD
201Tl or
exerc
dipyr
17 1,323 DM patients without clinically
apparent CAD
Stress e
patien
(n 
18 120 No history of MI or angina Dipyrid
(n 
19 203 DM patients without clinically
apparent CAD
Stress e
scinti
exerc
20 30 DM patients with peripheral
vascular disease but no evidence
of CAD
Dipyrid
(n 
21 136 DM asymptomatic for CAD or
age- and gender-matched
control subjects
201Tl sc
22 58 DM patients without clinically
apparent CAD
Exercise
(n 
23 925 DM patients without clinically
apparent CAD
Exercise
(n 
24 826 DM asymptomatic for CAD 201Tl or
exerc
dipyr
Overall study populations (the number of patients undergoing myocardial perfusion
n Asymptomatic Diabetes (DIAD) study (see text).
CAD  coronary artery disease; CV  cardiovascular; DM  diabetes mellitus;
mission computed tomography.t 2-year intervals, but more data are needed before a aefinitive interval can be pointed out. Patients with mod-
rate to severe perfusion abnormalities might need to be
eferred for invasive coronary angiography with intervention
f needed. Another issue that is unclear at present is the
recise definitions of the extent and severity of perfusion
bnormalities enabling the categorization of the patients as
ndicated in the preceding section.
SSUES OF FUTURE RESEARCH
any issues are currently unclear in the evaluation of
ymptoms of CAD
MPS Details Results
sestamibi SPECT 
 low-level exercise when
ruce 1) (n  522, 46%)
Abnormal MPS scans in 21% (16% of
perfusion abnormalities involved
5% of the left ventricle)
 exercise (n  56, 100%) Abnormal MPS scans in 21%
(significant coronary lesions in 16%)
ibi SPECT  exercise or
le (n  180, 100%)
Abnormal MPS scans in 26%
c sestamibi SPECT 
enosine, dobutamine, or
le (n  1,738, 100%)
Abnormal MPS scans in 59% (20%
were considered to represent high
CV risk)
ress 99mTc sestamibi
exercise or adenosine
, 100%)
Abnormal MPS scans in 39% of the
asymptomatic group; 51% of
patients short of breath; 44% of the
angina group
T  exercise or
le (n  158, 100%)
Abnormal MPS scans in 56%
c sestamibi SPECT 
enosine, dobutamine, or
le (n  1,427, 100%)
Abnormal MPS scans in 58% (20%
were considered to represent high
CV risk)
e 201Tl scintigraphy in
th positive exercise tests
%)
Positive MPS in 85 of 91 (93%)
patients with positive exercise test;
9.1% had evidence of SMI overall
(exercise or MPS)
stress 201Tl scintigraphy
3%)
Evidence of silent myocardial ischemia
in 30.7%
e or dipyridamole 201Tl
y in patients with a positive
t (n  105, 52%)
Evidence of SMI in 15.7% (exercise or
MPS)
201Tl scintigraphy
00%)
Abnormal scans suggesting SMI were
found in 47%; 37% displayed
evidence of prior silent MI
aphy (n  136, 100%) 23% reported positive MPS scan
l scintigraphy
00%)
17% displayed evidence of SMI on
scintigraphy
l scintigraphy
12%)
Abnormal MPS scan found in 59 of
112 (53%) patients with abnormal
or unequivocal exercise stress tests
(patients with negative stress tests
did not receive MPS)
c sestamibi SPECT 
enosine, dobutamine, or
le (n  826, 100%)
All had abnormal MPS by inclusion,
and 32% had high-risk MPS
graphy [MPS] is indicated in column 4); †Detection of Silent Myocardial Ischemia
myocardial infarction; SMI  silent myocardial ischemia; SPECT  single photonut S
9mTc
sine
le (B
ECT
estam
idamo
99mT
ise, ad
idamo
Tl/st
T 
1,737
PEC
idamo
99mT
ise, ad
idamo
xercis
ts wi
91, 9
amole
75, 6
xercis
graph
ise tes
amole
30, 1
intigr
201T
58, 1
201T
112,
99mT
ise, ad
idamo
scinti
MI symptomatic diabetic patients for CAD. In this viewpoint,
M
w
r
A
E
fi
d
p
(
e
b
i
T
o
c
n
r
m
h
o
B
a
i
d
r
p
f
i
c
s
w
o
a
f
p
h
t
t
b
t
s
a
e
M
b
t
e
p
e
s
w
f
i
h
w
m
t
r
i
h
m
s
e
t
i
n
n
b
p
t
d
t
t
r
h
s
i
(
s
t
(
k
h
n
i
h
a
d
t
r
F
f
s
758 Bax et al. JACC Vol. 48, No. 4, 2006
Diagnosing Silent Ischemia in Type 2 Diabetes August 15, 2006:754–60PS is proposed for screening for asymptomatic patients
ith diabetes. However, frequently patients with atheroscle-
osis might not necessarily have already developed ischemia.
t present, atherosclerosis can be assessed noninvasively by
BCT. This technique permits accurate detection of calci-
cations in the coronary arteries, reflecting atherosclerotic
egeneration (33). In the general population (including
atients with diabetes), various studies have shown that
cardiovascular) mortality is related to the severity of the
xtent of coronary artery calcium (34). The relationship
etween atherosclerosis on EBCT and perfusion abnormal-
ties on MPS was highlighted recently by Berman et al. (35).
he authors demonstrated on the one hand that ischemia
n MPS increased in parallel to increasing coronary artery
alcium scores but on the other hand that patients with a
ormal MPS frequently already have extensive atheroscle-
osis according to EBCT (35). Alternatively, patients with
inimal coronary artery calcium (scores 400) infrequently
ave ischemia on MPS.
Not much information is currently available on the value
f EBCT for evaluation of asymptomatic diabetic patients.
ecause EBCT (or MSCT) provides identification of CAD
t an earlier stage than MPS, it might be of particular
nterest to consider screening for CAD in asymptomatic
iabetic patients with EBCT and MPS sequentially, as
ecently proposed by Anand et al. (36). The authors
erformed a stepwise screening: patients were first screened
or atherosclerosis by EBCT, followed by screening for
schemia by MPS in patients with extensive coronary artery
alcium. With this approach, Anand et al. (36) demon-
trated that MPS was virtually never abnormal in patients
ithout substantial atherosclerosis on EBCT, whereas 48%
f patients with substantial atherosclerosis on EBCT had an
bnormal MPS. This stepwise evaluation could potentially
urther refine management of asymptomatic patients. In
atients with atherosclerosis on EBCT who do not (yet)
ave ischemia on MPS risk factor modification, medical
herapy and monitoring might be indicated, whereas pa-
igure 3. Potential algorithm on the implementation of myocardial per-
usion imaging (MPS) in risk stratification of diabetic patients without
ymptoms of coronary artery disease.ients with atherosclerosis on EBCT and ischemia should ce referred for invasive coronary angiography and interven-
ion if needed. Before implementation of this approach,
everal issues need to be resolved. First, the stepwise
pproach might be of interest, particularly from a cost-
ffectiveness point-of-view, and might avoid the use of
PS in all patients but rather allow a pre-selection for MPS
y a relatively inexpensive technique (EBCT). In that case,
he algorithm proposed in Figure 3 could be adapted, and an
ntrance criterion in addition to age 40 years could be the
resence of atherosclerosis on EBCT (or MSCT). How-
ver, what cutoff level on EBCT or MSCT (which calcium
core?) should be used to refer patients for SPECT? Second,
hat extent of ischemia is needed on MPS to refer a patient
or invasive evaluation?
In asymptomatic diabetic patients, information on this
ssue is not available. However, Hachamovitch et al. (37)
ave demonstrated in the general population that patients
ith 10% of the myocardium-exhibiting ischemia benefit
ore from revascularization as compared with medical
herapy in terms of short-term survival.
Third, if a patient is managed conservatively, when is
epeat testing indicated? The issue of repeat testing is an
mportant one. It is well known that a normal MPS study
as an excellent prognosis and that this prognostic value is
aintained over many years (25). However, it has also been
hown that in patients with diabetes and a normal MPS,
vents occur after 1 to 3 years (38,39). It has been suggested
hat in patients with diabetes the process of atherosclerosis
s characterized by a faster progress as compared with
ondiabetic patients. At present, the warranty period of a
ormal scan in patients with diabetes might be 1 to 3 years,
ut further research is needed to define the optimal warranty
eriod of a normal MPS, both in symptomatic and asymp-
omatic patients. This will eventually allow for a precise
efinition of how frequently follow-up MPS is needed in
hese patients.
The next issue that needs to be addressed is the following:
he clinical benefit from screening on patient outcome
emains to be proven. At present, no solid outcome studies
ave been presented demonstrating that implementation of
creening for ischemia will alter patient outcome. This
nformation will eventually be provided by the DIAD study
10). However, recent data from the Mayo Clinic provide
ome evidence concerning the value of SPECT in relation
o outcome in asymptomatic diabetic patients. Sorajja et al.
24) evaluated 826 asymptomatic diabetic patients without
nown CAD with abnormal MPS (261, or 32%, had a
igh-risk SPECT study). Revascularization (either coro-
ary artery bypass surgery or percutaneous coronary
ntervention) was performed in 54 of 261 patients with a
igh-risk SPECT study and was independently associ-
ted with improved survival. These are the first (nonran-
omized) data indicating that SPECT findings in asymp-
omatic patients influence outcome, but data from large
andomized trials (e.g., the DIAD study) are needed to
onfirm these findings.
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August 15, 2006:754–60 Diagnosing Silent Ischemia in Type 2 DiabetesFinally, considering the large population of asymptomatic
iabetic patients, the cost-effectiveness of screening is an
mportant issue; before implementation of any form of
creening, large outcome studies are needed, followed by
nalyses on the cost/benefit ratio.
ONCLUSIONS
ecent studies highlight the prevalence of CAD and silent
schemia in asymptomatic diabetic patients. Considering
he high cardiovascular event rate and mortality in diabetic
atients, risk stratification should be optimized in this
xponentially expanding population. Noninvasive imaging
ight be of particular value in this regard, as emerging
tudies with MPS have recently indicated. In particular, the
IAD trial has demonstrated the potential of MPS for
valuation of asymptomatic diabetic patients. Management
uidelines in cardiovascular medicine might be updated to
eflect the recent advances in this field, with potential use of
PS for risk stratification of asymptomatic diabetic pa-
ients. Still, many issues need to be resolved before screen-
ng of asymptomatic diabetic patients for CAD and silent
schemia can be implemented in clinical management.
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